A loss-of-function RNA interference screen for molecular targets in cancer. - Wikidata - wikimedia - TriplyDB

A loss-of-function RNA interference screen for molecular targets in cancer.

A loss-of-function RNA interference screen for molecular targets in cancer.

http://www.wikidata.org/entity/Q33237976

about

A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway The PICALM protein plays a key role in iron homeostasis and cell proliferation Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors Signalling of the BCR is regulated by a lipid rafts-localised transcription factor, Bright.Control of autophagic cell death by caspase-10 in multiple myeloma Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Cooperative epigenetic modulation by cancer amplicon genes Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Genomic screening with RNAi: results and challenges Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cancer systems biology: a network modeling perspective Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression The paracaspase MALT1: biological function and potential for therapeutic inhibition How I treat HIV-associated lymphoma Functional genomics lead to new therapies in follicular lymphoma Functional genomic and high-content screening for target discovery and deconvolution NF-κB in cellular senescence and cancer treatment RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Evaluation of Cancer Dependence and Druggability of PRP4 Kinase Using Cellular, Biochemical, and Structural Approaches Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181 B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells Oncogenically active MYD88 mutations in human lymphoma MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers Pooled screening for synergistic interactions subject to blocking and noise Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma Principles of cancer therapy: oncogene and non-oncogene addiction Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Genetic screens in human cells using the CRISPR-Cas9 system Inflammation meets cancer, with NF-κB as the matchmaker Clustering of CARMA1 through SH3-GUK domain interactions is required for its activation of NF-κB signalling.Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth MAGUK-controlled ubiquitination of CARMA1 modulates lymphocyte NF-kappaB activity.The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association.

P2860

Q21562478-944674AE-F269-4202-A675-907C175444D0 Q24298166-8C851AB1-9E4B-4B0A-AA1B-E9C9AF095CD8 Q24298225-8CADE23F-4C36-45FF-96AC-417A40D871C2 Q24305602-B066678D-BA6D-4EF1-9F32-48B8A512D633 Q24310569-10E2CAC1-51C8-4B84-B69B-41CED5EFC353 Q24337539-D8069304-1506-4006-8390-2E3B4CFA9B83 Q24597424-29B0B133-3CCB-460E-81AD-F21C93DD4337 Q24608701-EC7C6EBD-8E62-40B1-BAA5-0A718F17B570 Q24613755-7B467F94-45EC-4D4B-8367-1CF244233E23 Q24626537-E9733E3E-E37D-4144-858B-6F50D35A6185 Q24643447-56A34373-C7C0-4F0B-9E5E-6AF80E68143B Q24647664-06F76AC7-E638-4F2F-A8AA-FD7140D0EC20 Q24650086-CD775F4D-9C9F-4183-96B6-06D20FC3D67F Q24652565-00C3093A-3538-4D7D-B583-B5FF33D276B1 Q24652716-1833FD20-A67A-494C-86EB-F47CBB3D179D Q24657835-C716C24C-D6B9-4A62-A107-F538889B142D Q26778357-F56477D2-535C-4DB5-A78D-CB9F6724D5C2 Q26821860-491BCF08-3BB4-4400-AAEE-E3736C05CDFE Q26852415-43ABD87E-8F6C-40EC-A09F-A96FF6B9F16C Q26858957-FE7284E5-3C6C-4645-B1AD-E45A2ED67996 Q27007045-0F71BC72-78D5-4E61-9195-678CB9E7D361 Q27025675-9DBB8B84-C1F6-42E2-9456-5F54487CA05A Q27304386-4B203BD5-F03A-4152-81D4-D86D4562E873 Q27679866-9E29B993-D83A-42EA-83D6-1D91C3A28170 Q27685382-4690B6DE-3C53-4A8B-8234-ADCDB01E50EA Q28115962-B26847E6-E7C3-4E17-9EC3-E2C4E175F86C Q28117437-1C6E5C08-C534-4219-8956-E62667190123 Q28245018-33DBD8A0-BF0B-4060-92F5-12702F40A6C1 Q28301648-1E7431DF-5939-4BEA-8B12-CC522672F2C5 Q28306431-CDCE81C4-89A2-48BE-8393-071248656D0A Q28538785-D4E1BCF7-C28E-45D9-8067-F38E504AD9FE Q28649793-6FD1362C-5DC3-4515-870E-FFA73E028DFC Q29616779-2835A96C-F7F6-4567-A1E2-5BAD494EBD75 Q29617043-76E080C3-B9F4-447D-A3B3-A7A98D678BCF Q29617411-4941AC60-55A2-4A7B-A05E-A48D21F01681 Q29620242-6F23289E-0812-4227-BF09-1E56EA630CDD Q30009245-72E51460-BC3A-462F-9473-BC3A23123349 Q30009946-03FCE15B-8434-45A3-9668-85A50A57E394 Q30157021-99DC0F86-4D95-4796-A02F-CF3DB4C07171 Q30157639-C2C7A2EF-5133-403B-8DB2-DD73F6C8C19D

P2860

A loss-of-function RNA interference screen for molecular targets in cancer.

http://www.wikidata.org/entity/Q33237976

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A loss-of-function RNA interference screen for molecular targets in cancer.

@ast

A loss-of-function RNA interference screen for molecular targets in cancer.

@en

type

label

A loss-of-function RNA interference screen for molecular targets in cancer.

@ast

A loss-of-function RNA interference screen for molecular targets in cancer.

@en

prefLabel

A loss-of-function RNA interference screen for molecular targets in cancer.

@ast

A loss-of-function RNA interference screen for molecular targets in cancer.

@en

P1433

Q33237976-BE5F1910-9575-4F87-B1C6-176E96A86642

P1476

Q33237976-D4037F60-A70B-43BD-AB77-8C2C02249112

P2093

Q33237976-0503C145-AD39-48ED-BA99-0B455C18806E

Q33237976-1B241CF1-1E6A-46D7-99B5-7831E5DA30DF

Q33237976-2600BB56-127C-494C-9871-4BC7066118F4

Q33237976-3C7148F7-D66F-4A2B-BDD0-B0A3033F73DB

Q33237976-3F0A50D6-A6CC-45F6-B2CA-2E480AB66932

Q33237976-51FE90F4-352A-4BB3-817D-225F478D20B4

Q33237976-5D383267-73F9-4B16-AC02-9E291189569C

Q33237976-5D39F2CF-C86E-4688-AA45-7612DB3BDF93

Q33237976-7CD9FD62-0FFC-4C51-AE3A-253928ED6D9A

Q33237976-A526FE2F-E216-43A0-B988-AD6A3F63848A

P2860

Q33237976-073BB046-6CDF-4AF1-AAA7-4614D7200340

Q33237976-08073B75-2423-4AEF-A63F-D6B887149F1C

Q33237976-1908949C-00B3-4297-BC81-AE26EC3C57C4

Q33237976-1EE85686-68FB-46F2-A4B4-C92C0904849F

Q33237976-1F197EBD-FC36-41AD-A1FB-C6D0BD8CEB5E

Q33237976-305C362F-DE6B-4C1E-B717-F4ADE7684718

Q33237976-4424EF82-6911-4C4F-A1DC-BB6FD39A8F2E

Q33237976-4D63D6EF-0FD1-4422-8A13-7E7BB22B60D5

Q33237976-538529D7-54AD-43AC-8F0D-2880830F0D9F

Q33237976-5D909CD4-5CE4-4AAB-8DE0-858CD9C65698

P2888

Q33237976-925FD1E9-F7E7-4721-90B1-0157BA2506AC

P304

Q33237976-BEC9A6D6-72DE-476B-B792-44254F149B1B

P31

Q33237976-E10AA91E-393A-4736-B767-CF7EB2684118

P356

Q33237976-993013BB-82F2-4261-B27D-B2590C0C9244

P407

Q33237976-F281F55F-E8D4-4724-A9F4-8C967065A623

P433

Q33237976-D1292647-A3BF-4506-92EA-CC52AD4C7FA4

P478

Q33237976-659C0BC9-A333-4965-87CD-52C1DA968D0A

P577

Q33237976-2E4433B0-6170-4CEC-9A05-9ED4BBC41A2E

P5875

Q33237976-FD2420A6-93D5-44F9-BB18-E072E447DAF4

P6179

Q33237976-E2366228-5C01-4FBA-A51D-D8A0F60F37E1

P698

Q33237976-E7C5242C-86DD-4D32-AF3B-10E478BE0525

P356

P1433

P1476

A loss-of-function RNA interference screen for molecular targets in cancer.

@en

P2093

Georg Lenz

http://www.w3.org/2001/XMLSchema#string

Hong Zhao

http://www.w3.org/2001/XMLSchema#string

John Powell

http://www.w3.org/2001/XMLSchema#string

Laurence Lamy

http://www.w3.org/2001/XMLSchema#string

Liming Yang

http://www.w3.org/2001/XMLSchema#string

Lloyd T Lam

http://www.w3.org/2001/XMLSchema#string

Louis M Staudt

http://www.w3.org/2001/XMLSchema#string

R Eric Davis

http://www.w3.org/2001/XMLSchema#string

Sandeep Dave

http://www.w3.org/2001/XMLSchema#string

Vu N Ngo

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure

CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B

Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32)

P2888

P304

106-110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE04687

http://www.w3.org/2001/XMLSchema#string

P407

P433

7089

http://www.w3.org/2001/XMLSchema#string

P478

441

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7207545

http://www.w3.org/2001/XMLSchema#string

P6179

1000514179

http://www.w3.org/2001/XMLSchema#string

P698

16572121

http://www.w3.org/2001/XMLSchema#string